BackParadigm Biopharmaceuticals Limited Overview

Paradigm Biopharmaceuticals Limited Receivables

Latest receivables for PBIGF: $13M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$13.04M
↑ 104.66% YoYΔ $6.67M vs prior year quarter

Peer trimmed avg / median

Loading

Paradigm Biopharmaceuticals Limited Receivables History

Loading

Paradigm Biopharmaceuticals Limited vs. peers: Receivables Comparison

Loading

Paradigm Biopharmaceuticals Limited Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Paradigm Biopharmaceuticals Limited (PBIGF) FAQ

Paradigm Biopharmaceuticals Limited posts a receivables of $13M as of June 2026. That compares with $6.4M in the prior-year period — up 104.7% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Paradigm Biopharmaceuticals Limited's receivables was $6.4M. The latest reading is $13M — a 104.7% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Paradigm Biopharmaceuticals Limited's financial statement story. At $13M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for PBIGF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Paradigm Biopharmaceuticals Limited's other metric pages and overview cover the third.

Judging Paradigm Biopharmaceuticals Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $13M here, then scan peer and history charts to see if the gap is persistent.